Behavioral Rehabilitation Market Size Worth $540.84 Mn, Globally, by 2028 at 6.4% CAGR - Exclusive Report by The Insight Partners
February 15, 2022 09:03 ET
|
The Insight Partners
New York, Feb. 15, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Behavioral Rehabilitation Market Forecast to 2028 - COVID-19 Impact and Global Analysis By...
Polaryx Therapeutics Receives FDA Orphan Drug Designation for PLX-200 to Treat Krabbe Disease
September 02, 2021 00:00 ET
|
Polaryx Therapeutics, Inc
PARAMUS, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. ("Polaryx"), a biotech company developing small molecule therapeutics for lysosomal storage disorders, announced today...
FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer
October 23, 2019 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, Oct. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with...
FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
April 15, 2019 07:00 ET
|
FibroGen, Inc
SAN FRANCISCO, April 15, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today...
Equillium Granted U.S. FDA Orphan Drug Designations for EQ001 (itolizumab) for both the Prevention and Treatment of Acute Graft-Versus-Host Disease
February 07, 2019 08:08 ET
|
Equillium
LA JOLLA, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that the...
US FDA GRANTS PV-10 ORPHAN DRUG DESIGNATION FOR NEUROBLASTOMA
November 05, 2018 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company was granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA)...
Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
July 25, 2018 09:20 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 3 study follows positive 16-weeks Phase 2 data and further improvement in efficacy outcomes with open-label extension dosing at six months12-month 150 subject study with ACR/EULAR 2016 Total...
Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
July 20, 2018 09:20 ET
|
Corbus Pharmaceuticals Holdings, Inc.
– Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin – DM affects ~80,000 in the US, EU and Japan and has a 5-year mortality rate as high...
World-Record Matchstick Train arrives at Ripley's Times Square!
July 29, 2015 13:24 ET
|
Ripley's Believe It or Not! Times Square
NEW YORK, July 29, 2015 (GLOBE NEWSWIRE) -- The train may have left the station… and it's arrived at Ripley's Believe It or Not! Times Square! The conductor has slammed on the breaks to this...